GIPL names David R. Wells as fractional CFO

Global Innovative Platforms appointed finance veteran David R. Wells as fractional chief financial officer, effective Oct. 1, 2026, as the company advances its VetBreath Analytics veterinary diagnostics platform. Wells will help lead SEC reporting, financial planning and cash flow modeling while GIPL continues developing its breath-based canine heartworm test.

Why it matters: - Global Innovative Platforms is adding senior finance leadership as it develops VetBreath Analytics, its animal health diagnostics business. - The appointment is aimed at strengthening SEC reporting, accounting controls and financial planning at an early-stage public company. - The move comes as GIPL continues work on VetBreath Dx, its breath-based diagnostic platform for veterinary use.

What happened: - Global Innovative Platforms, Inc. appointed David R. Wells as fractional chief financial officer, effective Oct. 1, 2026. - Wells was also named principal financial officer and principal accounting officer. - Andrew Brown will remain chief executive officer and a member of the board of directors.

The details: - Wells has more than 30 years of experience in finance, operations and administration, with a background centered on medical device and technology companies. - He will oversee accounting and financial reporting functions. - His role includes support for SEC reporting, financial planning, cash flow planning and financial modeling. - GIPL said Wells will work through Atlas Bookkeeping, LLC under a Services Agreement dated Oct. 1, 2026. - Additional details are available in GIPL’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. - Since July 2021, Wells has owned Atlas Bookkeeping, LLC, where he provides CFO advisory services to public and private companies. - From August 2023 to May 2025, Wells served as chief financial officer of Envoy Medical, Inc. (Nasdaq: COCH). - From June 2021 to September 2022, Wells served as chief financial officer of GHS Investments, LLC, a private equity fund. - Since December 2022, Wells has served on the board of directors of HeartSciences, Inc. (Nasdaq: HSCS). - Wells holds a bachelor's degree in finance and entrepreneurship from Seattle Pacific University and an MBA from Pepperdine Graziadio Business School. - GIPL is a publicly traded company whose animal health diagnostics division, VetBreath Analytics, is developing a non-invasive, breath-based diagnostic platform. - The platform combines breath capture, gas chromatography, AI and chemometric modeling to analyze volatile organic compounds. - VetBreath Analytics is initially focused on canine heartworm detection. - The technology is in the development and validation stage. - GIPL intends to evaluate potential applications to additional diseases and species over time. - The company’s announcement also included social media links for VetBreath Analytics on LinkedIn and VetBreath Analytics on YouTube.

Between the lines: - The hiring suggests GIPL is preparing for more formal financial reporting as it pushes a development-stage diagnostics platform toward broader public-market scrutiny. - Wells’ mix of public-company finance and medtech experience fits a company that is still building both its product and its corporate infrastructure. - The company’s forward-looking statements highlight execution risk, financing needs and the uncertainty around any trading market for its stock.

What's next: - GIPL said Wells will help support ongoing financial planning and public reporting while VetBreath Analytics advances. - The company expects continued development, testing and potential regulatory work around VetBreath Analytics. - GIPL said it may pursue additional diseases and species as the platform matures. - Investors should expect future updates through SEC filings and company communications as development progresses.

The bottom line: - GIPL is pairing a development-stage animal diagnostics platform with a finance veteran who has public-company and medtech credentials.